R.R. Baliga/LinkedIn
Jul 1, 2026, 08:48
R.R. Baliga: The New JACC/ACC 2026 Statement Reinforces That DOAC Therapy Is Never One Size Fits All
R.R. Baliga, Editor-In-Chief of Textbook of Internal Medicine: Helping You Become a Great Doc, shared on LinkedIn:
”New JACC/ACC 2026 Scientific Statement spotlight: DOACs are now central to stroke and venous thromboembolism prevention—but not ‘one size fits all.’
The practical message: choose the right agent, dose correctly, avoid DOACs in mechanical valves and rheumatic mitral stenosis, reassess renal/liver function, bleeding risk, drug interactions, adherence, and cost.
In anticoagulation, the prescription is only the opening move; follow-up is where safety lives.”
Stay updated with Hemostasis Today.
-
Jul 1, 2026, 08:42Jacqui McCallum: AI Gave Me Leadership Feedback I Needed to Hear
-
Jul 1, 2026, 08:39Ryan Perry: 2027 Heart and Stroke Grants Now Open and Accepting Applications
-
Jul 1, 2026, 08:18Shruthi Narayan: Blood Clot Awareness Saves Lives Through NBCA
-
Jul 1, 2026, 07:23Peter Kouides: Understanding Anatomic Variant–Related Thrombosis
-
Jul 1, 2026, 06:47Abdul Mannan: Why Clotting Patients Bleed
-
Jul 1, 2026, 04:59Heghine Khachatryan: Empowering Women, Advancing Hemostasis, Transforming the Future
-
Jul 1, 2026, 04:12Bartosz Hudzik: Clinical Guidelines for Bleeding Risk During Bronchoscopy
-
Jun 30, 2026, 23:23Raymond Wang: Ozelle Joins the ICSH in Support of International Haematology Standards
-
Jun 30, 2026, 22:16Michelle Leona Cecil: A Visit Home to Wisconsin Highlighted the Power of Partnership in Bleeding Disorders Care